Health-Care Stocks the All-Stars Prescribe

Where do you turn for answers to your pressing medical questions? Do you get advice from pharmaceutical reps pushing their own products, or seek out the best independent physicians for an unbiased cure to what ails you? I'd imagine that most people want the best information available, from an independent source with no stake in their final decision. Why should your financial health be any different?

The 115,000-member Motley Fools CAPS investment community can provide the diagnosis your portfolio needs. All the stock rankings and pitches are provided by investors like you, independent thinkers who want their voices to be heard. The best members -- those proven to be the cream of the crop -- are given All-Star status. Overall, the community has demonstrated the wisdom of crowds, with five-star rated stocks outperforming the S&P 500 by an annualized 12% over the past 20 months.

Using the CAPS Screener, we can harness the power of the CAPS community to prescribe the best stocks for your portfolio.

I believe the health-care sector is a great place to invest right now, with rising medical costs and a partial immunity to the general economic cycle that's crippling consumer spending. I used the screen to find the best of the best. The following stocks -- all rated five stars -- have been given outperform ratings by at least 97% of the all-stars sharing an opinion.

Company

Recent Price

All-Star Outperform Ratings

Total All-Star Ratings

Percent of All-Stars Picking Outperform

Gilead Sciences (Nasdaq: GILD  )

$56.26

376

385

98%

Johnson & Johnson (NYSE: JNJ  )

$71.33

2187

2244

97%

Medtronic (NYSE: MDT  )

$54.07

293

301

97%

PDL Biopharma (Nasdaq: PDLI  )

$11.80

149

154

97%

Teva Pharmaceutical Industries (Nasdaq: TEVA  )

$48.32

305

313

97%

UnitedHealth Group (NYSE: UNH  )

$33.01

726

743

98%

Viropharma (Nasdaq: VPHM  )

$13.91

339

345

98%

Data provided by Motley Fool CAPS as of Aug. 18, 2008.

These aren't the kind of doctor's orders that should be followed blindly. Seek a second opinion, or better yet, perform your own due diligence before investing. But with so many intelligent investors in favor of these companies, they must be in good health and a wise place to begin your research.

Want to share your own diagnosis of your favorite (or least favorite) stocks? Stop by the Motley Fool CAPS community today.

Fool analyst Tony Arsta does not own shares of any company mentioned. He is postponing his annual checkup with his doctor because he was told the needles are afraid of him. Johnson & Johnson is an Income Investor selection. UnitedHealth Group is both an Inside Value and Stock Advisor recommendation. Try any of our Fool newsletter services free for 30 days. The Fool has a healthy disclosure policy.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 709283, ~/Articles/ArticleHandler.aspx, 10/22/2014 4:49:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement